US 4105782A
· Yu et al.
· 1978
[cited by applicant]
US 4256877A
· Karlsson et al.
· 1981
[cited by applicant]
US 4376118A
· Daher et al.
· 1983
[cited by applicant]
US 5009895A
· Lui
· 1991
[cited by applicant]
US 5310562A
· Margolin
· 1994
[cited by applicant]
US 5811130A
· Boettner et al.
· 1998
[cited by applicant]
US 5958420A
· Jenson
· 1999
[cited by applicant]
US 6365131B1
· Doshi et al.
· 2002
[cited by applicant]
US 7109246B1
· Hawtin
· 2006
[cited by applicant]
US 7816383B1
· Bradford et al.
· 2010
[cited by applicant]
US 8492412B2
· Magana Castro
· 2013
[cited by examiner]
US 8603965B2
· Zhou et al.
· 2013
[cited by applicant]
US 9408836B2
· Armendariz Borunda et al.
· 2016
[cited by applicant]
US 9949959B2
· Armendariz Borunda et al.
· 2018
[cited by applicant]
US 9962374B2
· Armendariz Borunda et al.
· 2018
[cited by applicant]
US 10383862B2
· Armendariz Borunda et al.
· 2019
[cited by applicant]
US 11013727B2
· Armendariz Borunda et al.
· 2021
[cited by applicant]
US 11040030B2
· Armendariz Borunda et al.
· 2021
[cited by applicant]
US 11052074B2
· Armendariz Borunda et al.
· 2021
[cited by applicant]
US 11766426B2
· Armendáriz Borunda et al.
· 2023
[cited by applicant]
US 12083106B2
· Armendáriz Borunda et al.
· 2024
[cited by applicant]
US 20030103941A1
· Crombleholme et al.
· 2003
[cited by applicant]
US 20040029946A1
· Arora et al.
· 2004
[cited by applicant]
US 20050059626A1
· Van Nest et al.
· 2005
[cited by applicant]
US 20060039931A1
· Scheiwe
· 2006
[cited by examiner]
US 20060051339A1
· Sivak
· 2006
[cited by applicant]
US 20060115503A1
· Goyal
· 2006
[cited by applicant]
US 20060198823A1
· Blatt
· 2006
[cited by applicant]
US 20070258946A1
· Blatt
· 2007
[cited by applicant]
US 20080025986A1
· Ozes et al.
· 2008
[cited by applicant]
US 20090047246A1
· Beigelman et al.
· 2009
[cited by applicant]
US 20090137354A1
· Chaudhuri
· 2009
[cited by applicant]
US 20100256031A1
· Wu et al.
· 2010
[cited by applicant]
US 20110034495A1
· Seiwert et al.
· 2011
[cited by applicant]
US 20110288134A1
· Maksumova et al.
· 2011
[cited by applicant]
US 20130225639A1
· Robinson et al.
· 2013
[cited by applicant]
US 20130245073A1
· Magana Castro et al.
· 2013
[cited by applicant]
US 20130345165A1
· Smith et al.
· 2013
[cited by applicant]
US 20150148382A1
· Armendariz Borunda
· 2015
[cited by examiner]
US 20150231098A1
· Magana Castro et al.
· 2015
[cited by applicant]
US 20160338997A1
· Ryan
· 2016
[cited by examiner]
US 20180066228A1
· Smith et al.
· 2018
[cited by applicant]
US 20180214434A1
· Armendariz Borunda et al.
· 2018
[cited by applicant]
US 20180353448A1
· Magana Castro et al.
· 2018
[cited by applicant]
US 20190262325A1
· Armendariz Borunda et al.
· 2019
[cited by applicant]
US 20210093593A1
· Magana Castro et al.
· 2021
[cited by applicant]
US 20230117397A1
· Aguilar-Cordova et al.
· 2023
[cited by applicant]
US 20230181550A1
· Armendáriz Borunda et al.
· 2023
[cited by applicant]
US 20240216350A1
· Armendáriz Borunda et al.
· 2024
[cited by applicant]
US 20250213539A1
· Armendariz Borunda et al.
· 2025
[cited by applicant]
US 20250221949A1
· Magana Castro et al.
· 2025
[cited by applicant]
US 20250325530A1
· Armendariz Borunda et al.
· 2025
[cited by applicant]
CA 2764043A1
· 2010
[cited by applicant]
CN 1701793A
· 2005
[cited by applicant]
CN 101972225A
· 2011
[cited by applicant]
CN 101972236A
· 2011
[cited by applicant]
CN 102488660A
· 2012
[cited by applicant]
CN 102670600A
· 2012
[cited by applicant]
CN 102670632A
· 2012
[cited by applicant]
CN 103550242A
· 2014
[cited by applicant]
EP 1113798A1
· 2001
[cited by applicant]
EP 1356816A1
· 2003
[cited by applicant]
EP 2177220A1
· 2010
[cited by applicant]
EP 2832354A1
· 2015
[cited by applicant]
EP 2907506A1
· 2015
[cited by applicant]
ES 2377932T3
· 2012
[cited by applicant]
ES 2530049T3
· 2015
[cited by applicant]
JP 8510251A
· 1996
[cited by applicant]
JP 2002506820A
· 2002
[cited by applicant]
JP 2006503026A
· 2006
[cited by applicant]
JP 2011506446A
· 2011
[cited by applicant]
JP 2014505733A
· 2014
[cited by applicant]
JP 2014522861A
· 2014
[cited by applicant]
JP 2015513359A
· 2015
[cited by applicant]
JP 2015526528A
· 2015
[cited by applicant]
JP 2016515525A
· 2016
[cited by applicant]
JP 2016517444A
· 2016
[cited by applicant]
KR 1020140057248A
· 2014
[cited by applicant]
KR 1020140146A
· 2014
[cited by applicant]
KR 1020170074497A
· 2017
[cited by applicant]
MX 2013008151A
· 2013
[cited by applicant]
WO WO9710712A1
· 1997
[cited by applicant]
WO WO1999047140A1
· 1999
[cited by applicant]
WO WO2000016775A1
· 2000
[cited by applicant]
WO WO2004073713A1
· 2004
[cited by applicant]
WO WO2004078193A1
· 2004
[cited by applicant]
WO WO2004078194A1
· 2004
[cited by applicant]
WO WO2004078207A1
· 2004
[cited by applicant]
WO WO2004089283A2
· 2004
[cited by applicant]
WO WO2005000227A2
· 2005
[cited by applicant]
WO WO2005013917A2
· 2005
[cited by applicant]
WO WO2005037214A2
· 2005
[cited by applicant]
WO WO2006122154A2
· 2006
[cited by applicant]
WO WO2007038315A2
· 2007
[cited by applicant]
WO WO2008107873A1
· 2008
[cited by applicant]
WO WO2009022899A1
· 2009
[cited by applicant]
WO WO2010054294A1
· 2010
[cited by applicant]
WO WO2010132864A1
· 2010
[cited by applicant]
WO WO2012106382A1
· 2012
[cited by applicant]
WO WO2013012307A1
· 2013
[cited by applicant]
WO WO2013181691A1
· 2013
[cited by applicant]
WO WO2014036487A1
· 2014
[cited by applicant]
WO WO2014055548A1
· 2014
[cited by applicant]
WO WO2016185182A1
· 2016
[cited by applicant]
WO WO2017104725A1
· 2017
[cited by applicant]
WO WO2018088886A1
· 2018
[cited by applicant]
WO WO2018189012A1
· 2018
[cited by applicant]
WO WO2019035705A2
· 2019
[cited by applicant]
WO WO2020227331A1
· 2020
[cited by applicant]
International Preliminary Report on Patentability dated Jan. 28, 2018 for Application No. PCT/MX2017/000129.
[cited by applicant]
International Search Report and Written Opinion dated Apr. 9, 2018 for Application No. PCT/MX2017/000129.
[cited by applicant]
International Search Report and Written Opinion, PCT/MX2018/000071, dated Mar. 28, 2019, 12 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/MX2018/000071, dated Jul. 19, 2019, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability dated Aug. 7, 2013 for Application No. PCT/MX2012/000067.
[cited by applicant]
International Search Report and Written Opinion dated Nov. 22, 2012 for Application No. PCT/MX2012/000067.
[cited by applicant]
International Preliminary Report on Patentability dated Dec. 1, 2009 for Application No. PCT/MX2008/000107.
[cited by applicant]
International Search Report dated Dec. 9, 2008 for Application No. PCT/MX2008/000107.
[cited by applicant]
International Search Report and Written Opinion dated Jun. 5, 2013 for Application No. PCT/MX2013/000027.
[cited by applicant]
International Preliminary Report on Patentability dated Dec. 19, 2014 for Application No. PCT/MX2013/000099.
[cited by applicant]
International Search Report and Written Opinion dated Aug. 8, 2014 for Application No. PCT/MX2013/000099.
[cited by applicant]
International Search Report and Written Opinion, for Application No. PCT/MX2019/000093, dated Aug. 4, 2020.
[cited by applicant]
International Preliminary Report on Patentability, for Application No. PCT/MX2019/000093, dated Jan. 12, 2021.
[cited by applicant]
[No Author Listed] Understanding Acne Treatment. Retrieved from https:/lwww.Webmd.com/skin-problems-and-treatnnents/acne/understanding-acne-treatnnent#5 on Feb. 4, 2019. 5 pages.
[cited by applicant]
[No Author Listed] allicinnow, “allicin,” retrieved online at: http://www.allicinnow.com/allicin/acne-treatmentl, 2 pages (2010).
[cited by applicant]
Armendariz-Borunda et al., A Controlled Clinical Trial With Pirfenidone in the Treatment of Pathological Skin Scarring Caused by Bums in Pediatric Patients,Annals of Plastic Surgery, vol. 68(1):22-28 (2012).
[cited by applicant]
Database WPI Section Ch, Week 200629 Thomson Scientific, London, GB; Class B03, AN 2006-273778, WU, Use of pirfenidone for treating hepatic injury and necrosis and acute lung injury. Shanghai Genomics) p. 7; (2005).
[cited by applicant]
Database WPI Section Ch, Week 201139 Thomson Scientific, London, GB; Class A96, AN 2011-D92901, Li X: Sustained-release tablet comprises pirfenidone, substance capable of releasing active ingredient, and additive. Med P…
[cited by applicant]
Database WPI Section Ch, Week 201427 Thomson Scientific, London, GB; Class A96, AN 2014-F77081, Deng C et al., Pharmaceutical composition used for treating hepatic fibrosis, liver fibrosis, liver cirrhosis, and liver ca…
[cited by applicant]
Garcia et al., Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. Dec. 2002;37(6):797-805.
[cited by applicant]
Josling, Peter Josling's PowerPoint on AllicinCenter Products and Their Uses, retrieved from the internet at: http://allicincenter.com/reference.php?id=products, 15 pages (2013).
[cited by applicant]
Macias-Barragan et al., Methyl-1-Phenyl-2- (1H)-Pyridone Treatment Improves Markers of Hepatic Function and Fibrosis in Steatosis Included By High Fat/Carbohydrate Diet. J Hepatology, Abstract of the International Liver…
[cited by applicant]
Macias-Barragan et al., Pirfenidone LP activates PPARalpha and LXRalpha and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet. Hepatology…
[cited by applicant]
Nakanishi et al., Pirfenidone inhibits the induction of iNOS stimulated by interleukin-lbeta at a step of NF-kappaE DNA binding in hepatocytes. J Hepatology, vol. 41(5):730-736 (2004).
[cited by applicant]
Ojeda-Duran et al., Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients. J Renal Hepatic Disorders. 2020;4(1):22-30.
[cited by applicant]
Ozes et al., Preclinical activity of pirfenidone (5-methyl -lphenyl -2 (IH) -pyri done) in cell-based models of nonalcoholic steatohepatitis. Hepatology, Abstract 697, 2003;34(4): 495A.
[cited by applicant]
Park et al., Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. J Korean Med Sci. Aug. 2003;18(4):527-33.
[cited by applicant]
Tiwari et al., Applications of Complementary Polymers in HPMC Hydrophilic Extended Release Matrices. Drug Delivery Technology, Formulating Hydrophilic Matrix Systems, 2009;9(7), 7 pages.
[cited by applicant]
Veras-Castillo et al., Controlled clinical trial with pirfenidone in the treatment of breast capsular contracture:Association ofTGF polymorphisms. Annals Plastic Surgery. 2014;70(1):16-22.
[cited by applicant]
International Search Report and Written Opinion, for Application No. PCT/US2021/027335, dated Jul. 12, 2021.
[cited by applicant]
Wang et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCOV) in vitro. Cell Res. Mar. 2020;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub Feb. 4, 2020. PMID: 320200…
[cited by applicant]
International Preliminary Report on Patentability dated Oct. 9, 2014 for Application No. PCT/MX2013/000027.
[cited by applicant]
Partial Supplementary European Search Report, dated Apr. 16, 2024 for EP Application No. 21788910.4.
[cited by applicant]
Extended European Search Report, dated Jul. 12, 2024 for EP Application No. 21788910.4.
[cited by applicant]
International Preliminary Report on Patentability, dated Oct. 27, 2022 for Application No. PCT/US2021/027335.
[cited by applicant]
[No Author Listed], Application of addition polymers in hydrophilic hydroxypropyl methylcellulose extended release matrix tablets. Colorcon China, Inc. China Academic Journal Electronic Publishing House. 2022. 3 pages.
[cited by applicant]
[No Author Listed], Efficacy of Pirfenidone Plus MODD in diabetic foot ulcers. NCT02632877. Last updated: Dec. 17, 2015. Retrieved May 17, 2022 from <https://clinicaltrials.gov/ct2/show/NCT02632877?term=NCT02632877>. 8 …
[cited by applicant]
[No Author Listed], History of Changes for Study: NCT04282902; A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection. Feb. 21, 2020. Accessed from <https://classic.clinicaltrials.go…
[cited by applicant]
[No Author Listed], Mexico's coronavirus death toll is likely 60% higher than confirmed numbers. Reuters. Mar. 29, 2021. Accessed from <https://www.nbcnews.com/news/latino/mexicos-coronavirus-death-toll-likely-60-higher…
[cited by applicant]
[No Author Listed], Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)—United States, Feb. 12-Mar. 16, 2020. CDC COVID-19 Response Team. MMWR Morb Mortal Wkly Rep. Mar. 27, 2020;69(12):343-346. doi:…
[cited by applicant]
Armendáriz-Borunda et al., A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. Nov. 2006;55(11):1663-5. doi: 10.1136/gut.2006.107136.
[cited by applicant]
Azuma et al., Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. May 1, 2005;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub Jan. 21, 200…
[cited by applicant]
Bednarek et al., Skin Antiseptics. In:StatPearls. Jan. 2022. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK507853 Jun. 9, 2022.
[cited by applicant]
Bhatraju et al., Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. N Engl J Med. May 21, 2020;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub Mar. 30, 2020.
[cited by applicant]
Bruss et al., Pharmacokinetics of orally administered pirfenidone in male and female beagles. J Vet Pharmacol Ther. Oct. 2004;27(5):361-7. doi: 10.1111/j.1365-2885.2004.00612.x.
[cited by applicant]
Cain et al., Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol. Dec. 1998;20(12):685-95. doi: 10.1016/s0192-0561(98)00042-3.
[cited by applicant]
Chen et al., Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. Jun. 2011;259(3):749-56. doi: 10.1148/radiol.11101942. Epub Apr. 1, 201…
[cited by applicant]
Choudhuri et al., SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality. PLoS One. Dec. 31, 2020;15(12):e0244777. doi: 10.1371/journal.pone.0244777.
[cited by applicant]
Didiasova et al., Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J. May 2017;31(5):1916-1928. doi: 10.1096/fj.201600892RR. Epub Feb. 1, 2017.
[cited by applicant]
Estes et al., Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy. J Infect Dis. Mar. 1, 2015;211(5):744-54. d…
[cited by applicant]
Flores-Contreras et al., Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. Bmc Gastroenterol. Jul. 27, 2014;14:131. doi: …
[cited by applicant]
Gancedo et al., Pirfenidone prevents capsular contracture after mammary implantation. Aesthetic Plast Surg. Jan. 2008;32(1):32-40. doi: 10.1007/s00266-007-9051-4.
[cited by applicant]
Gao et al., Pirfenidone Alleviates Choroidal Neovascular Fibrosis through TGF-β/Smad Signaling Pathway. J Ophthalmol. Feb. 10, 2021;2021:8846708. doi: 10.1155/2021/8846708.
[cited by applicant]
Gennaro, Remington's Pharmaceutical Sciences. 1990; 18th Ed. pp. 1288-1289, 1291-1292.
[cited by applicant]
Gu et al., Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model. Cryobiology. Jun. 2018;82:106-111. doi: 10.1016/j.…
[cited by applicant]
Guo et al., Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model. Toxicol Lett. Jan. 2019;300:59-66. doi: 10.1016/j.toxlet.2018.10.019. Epub Oct. 28, 2018.
[cited by applicant]
Güvenç et al., Pirfenidone Attenue Epidural Fibrosis In Rats By Suppressing TNF-α, IL-1, and α-SMA. J Turk Spin Surg. Jul. 2018;29(3):133-40.
[cited by applicant]
Horie et al., Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med. Dec. 2020;46(12):2265-2283. doi: 10.1007/s00134-020-06141-z. Epub Jul. 11, 2020.
[cited by applicant]
Huang et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. Feb. 15, 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub Jan. 24, 2020. Erratum in: Lancet. Jan…
[cited by applicant]
Ishinaga et al., TGF-β induces p65 acetylation to enhance bacteria-induced NF-κB activation. EMBO J. Feb. 21, 2007;26(4):1150-62. doi: 10.1038/sj.emboj.7601546. Epub Feb. 1, 2007.
[cited by applicant]
Janka-Zires et al., Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study. J Diabetes Res. 2016;2016:7340641. doi: 10.1155/2016/7340641. Epub Jul. 10, 2016.
[cited by applicant]
King et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. May 29, 2014;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub May 18, 2014. Erratum in: N Engl J Med. Sep. 18, 2…
[cited by applicant]
Loomba et al., GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. Nov. 2018;155(5):1463-1473.e6. doi: 10.1053/j.gastro.2018.07.027. Epub Jul. 27, …
[cited by applicant]
Lopez-De La Mora et al., Role and New Insights of Pirfenidone in Fibrotic Diseases. Int J Med Sci. Oct. 14, 2015;12(11):840-7. doi: 10.7150/ijms.11579.
[cited by applicant]
Mccommis et al., Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism. Cell Mol Gastroenterol Hepatol. 2019;7(2):275-284. doi: 10.1016/j.jcmgh.2018.09.017. Epub Oct. 10, 2018.
[cited by applicant]
Moises et al., A Double-blind, Multicenter Study Comparing Pirfenidone and Prednisone for Moderate-to-Severe Pulmonary Fibrosis. Chest J. Jan. 1, 2003;124(4)Suppl:116S. Abstract Only. doi: 10.1378/chest.124.4_MeetingAbs…
[cited by applicant]
Nagai et al., Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med. Dec. 2002;41(12):1118-23. doi: 10.2169/internalmedicine.41.1118.
[cited by applicant]
Nakazato et al., A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. Jun. 20, 2002;446(1-3):177-85. doi: 10.1016/s0014-2999(02)01758-2.
[cited by applicant]
Oku et al., Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. Jun. 20, 2002;446(1-3):167-76. doi: 10.1016/s0014-2999(02)01757-0.
[cited by applicant]
Olivas-Martinez et al., In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. PLoS One. Feb. 3, 2021;16(2):e0245772. do…
[cited by applicant]
Orozco et al., Economic evaluation of topical administration of gel with pirfenidone (KITOSCELL Q®) as an adjuvant in the treatment of patients with diabetic foot ulcers. PMD63. Value in Health. May 2017; 20(5):A246.
[cited by applicant]
Pepin, K., Liver Fat Does Not Affect Liver Stiffness Measured with MR Elastography. Resoundant Fact Sheet. 2019. Accessed from < https://www.resoundant.com/single-post/2019/05/21/fact-sheet-liver-fat-does-not-affect-liv…
[cited by applicant]
Raghu et al., Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. Apr. 1999;159(4 Pt 1):1061-9. doi: 10.…
[cited by applicant]
Rao et al., A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. Sep. 2020;9(3):573-586. doi: 10.1007/s40121-020-00324-3. Epub Jul. 28, 2020. Erratum in: Inf…
[cited by applicant]
Ravishankar et al., A brief review on Pleiotropic effects of Pirfenidone—novel and ongoing outcomes. Int J Res Dev Pharm Life Sci. Jan.-Feb. 2019;8(1):6-14. doi: 10.21276/IJRDPL.2278-0238.2019.8(1).6-14.
[cited by applicant]
Rubino et al., Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. Aug. 2009;22(4):279-85. doi: 10.1016/j.pupt.2009.03.003. Epub Mar. 27, 2009.
[cited by applicant]
Ruwanpura et al., Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. Am J Respir Cell Mol Biol. Apr. 2020;62(4):413-422. doi: 10.1165/rcmb.2019-0328TR.
[cited by applicant]
Salazar-Montes et al., Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol. Oct. 24, 2008;595(1-3):69-77. doi: 10.1016/j.ejphar.2008.06.110. Epub Jul. 9, 2008.
[cited by applicant]
Schaefer et al., Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. Jun. 2011;20(120):85-97. doi: 10.1183/09059180.00001111.
[cited by applicant]
Seifirad, S., Pirfenidone: A novel hypothetical treatment for COVID-19. Med Hypotheses. Nov. 2020;144:110005. doi: 10.1016/j.mehy.2020.110005. Epub Jun. 17, 2020.
[cited by applicant]
Selman et al., Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. Jan. 16, 2001;134(2):136-51. doi: 10.7326/0003-4819-134-2-200101160-0…
[cited by applicant]
Selvaraj et al., Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NALFD: A systematic review and meta-analysis. J Hepatol. Oct. 2021;75(4):770-785. doi: 10.1016/j.jhep.2021.04.044. Epu…
[cited by applicant]
Suga et al., Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol. Sep. 1995;47(4):287-91. doi: 10.1016/s0940-2993(11)80261-7.
[cited by applicant]
Sun et al., Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. Histochem Cell Biol. Feb. 2016;145(2):201-11. doi: 10.10…
[cited by applicant]
Sun et al., Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. Eur Respir J. Sep. 15, 2018;52(3):1702314. doi: 10.1183/13993003.02314-2017.
[cited by applicant]
Vitiello et al., COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr Clin Med. 2020;2(10):1709-1712. doi: 10.1007/s42399-020-00487-7. Epub Aug. 27, 2020.
[cited by applicant]
Wang et al., Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. Jul. 28, 2020;71(15):769-777. doi: 10.1093/cid/ciaa272.
[cited by applicant]
Wilson et al., Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis? Am J Respir Cell Mol Biol. Apr. 2019;60(4):386-387. doi: 10.1165/rcmb.2018-0387ED.
[cited by applicant]
Wu et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Jul. 1, 2020;180(7):934-943. doi: 10.1001/jamai…
[cited by applicant]
Wygrecka et al., Pirfenidone exerts anti-fibrotic effects through Inhibition of GLI transcription factors. Pneumologie. Feb. 21, 2018;72(S 01):S114-5. doi: 10.1055/s-0037-1619431.
[cited by applicant]
Zhang et al., Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging. Jan. 2020;51(1):25-42. doi: 10.1002/jmri.26716. Epub Mar. 12, 2019. Author Manuscript, 32 …
[cited by applicant]
Zhang et al., Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol. May 1998;26 Suppl 1:S74-6. doi: 10.1111/j.1442-9071.1998.tb01380.x.
[cited by applicant]
Zhou et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Mar. 28, 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3…
[cited by applicant]
Ziol et al., Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. Jan. 2005;41(1):48-54. doi: 10.1002/hep.20506.
[cited by applicant]
No Author Listed, A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19). World Health Organization International Cl…
[cited by applicant]
No Author Listed, Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis: a prospective exploratory experimental medical study. World Health Organization Inte…
[cited by applicant]
Dai et al., High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China. Int J Infect Dis. Jun. 2020;95:106-112. doi: 10.1016/j.ijid.2020.04.003. Epub Apr. 6, 2020.
[cited by applicant]
Lewis, T., Here's what we know about the most touted drugs tested for COVID-19. Scientific American. Apr. 16, 2020. Accessed May 16, 2025 from <https://www.scientificamerican.com/article/heres-what-we-know-about-the-mos…
[cited by applicant]
Lovelace et al., Dr. Anthony Fauci warns US could ‘be in for a bad fall’ if coronavirus treatments don't work. CNBC, Health and Science. Apr. 28, 2020. Accessed May 16, 2025 from <https://rb.gy/a2pf8q>. 3 pages.
[cited by applicant]
Xu et al., Key Points of Clinical and CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) Imported Pneumonia Based On 21 Cases Analysis. medRxiv. Mar. 6, 2020. doi: 10.1101/2020.03.03.20030775. 14 pages.
[cited by applicant]
*U.S. Appl. No. 18/965,593, filed Dec. 2, 2024, Armendáriz Borunda et al.
[cited by applicant]
*U.S. Appl. No. 17/328,685, filed May 24, 2021, Armendáriz Borunda et al.
[cited by applicant]
*U.S. Appl. No. 17/351,151, filed Jun. 17, 2021, Armendáriz Borunda et al.
[cited by applicant]
*U.S. Appl. No. 17/390,368, filed Jul. 30, 2021, Magana Castro et al.
[cited by applicant]
PCT/US2021/027335, Jul. 12, 2021, International Search Report and Written Opinion.
[cited by applicant]